Evaluation of Indication-Based Pricing for Oncology Biologic

In The News,

May 24 2022

Evaluation of Indication-Based Pricing for Oncology Biologic

Evaluated potential strategies to implement Indication Based Pricing (IBP) and understand the impact to ASP and other reimbursement/payment metrics surrounding an oncology biologic. ADVI did this by identifying key operational issues related to implementing IBP and quantitatively modeling the impact of discounting to product ASP.